RETRACTED ARTICLE: Moringa isothiocyanate complexed with α-cyclodextrin: a new perspective in neuroblastoma treatment

Abstract

BackgroundSeveral lines of evidence suggest the consume of natural products for cancer prevention or treatment. In particular, isothiocyanates (ITCs) exerting anti-cancer properties, have received great interest as potential chemotherapeutic agents.This study was designed to assess the anti-proliferative activities of a new preparation of Moringa oleifera-derived 4-(α-L-rhamnopyranosyloxy)benzyl ITC (moringin) complexed with alpha-cyclodextrin (moringin + α-CD; MAC) on SH-SY5Y human neuroblastoma cells. This new formulation arises in the attempt to overcome the poor solubility and stability of moringin alone in aqueous media.MethodsSH-SY5Y cells were cultured and exposed to increasing concentrations of MAC (1.0, 2.5 and 5.0 μg). Cell proliferation was examined by MTT and cell count assays. The cytotoxic activity of the MAC complex was assessed by lactate dehydrogenase (LDH) assay and trypan blue exclusion test. In addition, western blotting analyses for the main apoptosis-related proteins were performed.ResultsTreatment of SH-SY5Y cells with the MAC complex reduced cell growth in concentration dependent manner. Specifically, MAC exhibited a potent action in inhibiting the PI3K/Akt/mTOR pathway, whose aberrant activation was found in many types of cancer. MAC was also found to induce the nuclear factor-κB (NF-κB) p65 activation by phosphorylation and its translocation into the nucleus. Moreover, treatment with MAC was able to down-regulate MAPK pathway (results focused on JNK and p38 expression). Finally, MAC was found to trigger apoptotic death pathway (based on expression levels of cleaved-caspase 3, Bax/Bcl-2 balance, p53 and p21).ConclusionThese findings suggest that use of MAC complex may open novel perspectives to improve the poor prognosis of patients with neuroblastoma.

Human gingival mesenchymal stem cells pretreated with vesicular moringin nanostructures as a new therapeutic approach in a mouse model of spinal cord injury

“…However, MOR, as well as other isothiocyanates, is not soluble in water that results in stability problems for the delivery. This difficulty, as we previously described, can be overcome by complexation of MOR with cyclodextrins, cyclic oligosaccharides able to form water–soluble inclusion complexes with small molecules (Giacoppo, Iori, Rollin, Bramanti, & Mazzon, ; Mathiron et al, ). In this work, we proposed the liposomes as another moringin formulation able to improve its solubility and stability in an aqueous medium.…”

New aspects of antiproliferative activity of 4-hydroxybenzyl isothiocyanate, a natural H2S-donor

“…4 ). Both SH-SY5Y and U87MG cancer cell lines contain wild-type p53 protein (Mustafa Rizvi et al 2014 ; Janardhanan et al 2009 ; Cerrato et al 2001 ; Giacoppo et al 2017 ). It seems that inhibition of p53 protein in SH-SY5Y cells can be also associated with S-sulfuration or induction of oxidative stress in these cells.…”

The α-Cyclodextrin/Moringin Complex: A New Promising Antimicrobial Agent against Staphylococcus aureus

“…The soluble complex MOR/α-CD was obtained by adding 103 mg of solid MOR to a solution of 300 mg α-CD (Wacker Chemie AG, München, Germany) in 3.0 mL of water, with a 1:1 M ratio of the two constituents [9]. The resulting aqueous solution was filtered with a 0.45 μm filter, then freeze-dried (Edwards model DO1; Milan, Italy) [8]. One gram of the complex contained 242.45 mg MOR.…”

“…Furthermore, MOR inhibits S. aureus growth, showing bactericidal effect [6,7]. Similarly to most ITCs, MOR is very poorly soluble in water and, in order to overcome this problem, a new complex of MOR with α-CD (MOR/α-CD) was developed [8] and characterized by combining NMR and mass spectrometry experiments [9]. Although the therapeutic potential of MOR/α-CD was recently investigated [8,10], its potential bacteriostatic/bactericidal role has not yet been evaluated.…”

“…Similarly to most ITCs, MOR is very poorly soluble in water and, in order to overcome this problem, a new complex of MOR with α-CD (MOR/α-CD) was developed [8] and characterized by combining NMR and mass spectrometry experiments [9]. Although the therapeutic potential of MOR/α-CD was recently investigated [8,10], its potential bacteriostatic/bactericidal role has not yet been evaluated. In this study, we investigated whether MOR/α-CD could exert an in vitro antibacterial effect against S. aureus reference strains (ATCC 25923, ATCC 6538, and ATCC BAA-977), previously assessed for their sensitivity to MOR.…”